SOT Annual Meeting and ToxExpo 2026

Presenter: Clare Gilmer, Senior Research Scientist, Certara

地点： Room 23B

In silico tools that rely on input of molecular structure only can flag-up potential safety issues prior to even molecule synthesis and therefore support early de-risking of the drug discovery pipeline. In alignment with the FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies, we are developing new approach methodologies (NAMs) which will help predict some of the most common and impactful preclinical safety issues: hepatotoxicity, QT prolongation and off-target safety.

Presenters: Kevin Snyder, Director of Product, Certara and Melissa Cunningham, Executive Director, Product Management, Certara

地点： Room 23B

This session will showcase two complementary innovations for toxicology data analysis. First, learn how Certara’s SEND Data Lake enables structured storage and integration of CDISC-SEND-formatted study data to support advanced analytics, predictive modeling, and large-scale cross-study analysis using open-source tools. Second, explore AI-enabled functionality designed to help users rapidly identify endpoints of interest and automatically generate narrative summaries that describe the toxicological relevance of study findings. Together, these approaches accelerate interpretation and decision-making within a collaborative data science framework.

Presenter: Barira Islam, Associate Principal Scientist, Certara

地点： Ballroom 6F

This presentation is part of the session, “NAM in vitro Assessment of Intestinal Metabolism to Inform PBPK Modeling of Bioavailability and Systemic Exposure”

Authors: Y. Chen1, T. Arndt1, E. Debien1, K. Snyder2, S. Nakatsuji1, J. Forget1, and W. Davis1. 1Altasciences, Seattle, WA; and 2Certara, Radnor, PA.

Poster information: Abstract #4054 | Poster Board Number G528 | Poster Session: Safety Assessment: Pharmaceutical-Drug Development I

Authors: K. J. Sadko1, A. VandenBussche1, M. Bailie2, and A. Lauver1. 1Michigan State University, East Lansing, MI; and 2Certara Inc., Radnor, PA.

Poster information: Abstract #4713 | Poster Board Number F504 | Poster Session: Safety Assessment: Pharmaceutical-Drug Development II